Busulfan and melphalan as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma
- 1 October 1995
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 91 (2) , 380-386
- https://doi.org/10.1111/j.1365-2141.1995.tb05307.x
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- THE MOLECULAR GENETICS OF ANTITHROMBIN DEFICIENCYBritish Journal of Haematology, 1994
- Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials.Journal of Clinical Oncology, 1992
- Allogeneic Bone Marrow Transplantation in Multiple MyelomaNew England Journal of Medicine, 1991
- Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients.Journal of Clinical Oncology, 1991
- Melphalan/prednisone versus drug combinations for plasma cell myelomaEuropean Journal of Haematology, 1989
- INTENSIVE TREATMENT OF MULTIPLE MYELOMA AND CRITERIA FOR COMPLETE REMISSIONThe Lancet, 1989
- In vitro studies of ways to overcome resistance to VAMP‐high dose melphalan in the treatment of multiple myelomaBritish Journal of Haematology, 1989
- Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantationCancer Chemotherapy and Pharmacology, 1989
- Regimen-related toxicity in patients undergoing bone marrow transplantation.Journal of Clinical Oncology, 1988
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958